Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Pirtobrutinib provides longer progression-free survival and is safer than idelalisib-rituximab and bendamustine-rituximab for treating relapsed CLL.
The first-line combination pirtobrutinib, venetoclax, and obinutuzumab produces deep remissions in the majority of patients with CLL.
The combination of pirtobrutinib, venetoclax, and rituximab was very effective and produced deep remissions in patients with relapsed / refractory CLL.
Pirtobrutinib is approved for the treatment of CLL and SLL in those whose disease has either relapsed or become refractory after having been previously treated
Long-term follow-up shows that pirtobrutinib is effective in patients with CLL who have received multiple prior lines of therapy.
The majority of CLL patients who had previously relapsed on covalent BTK inhibitors responded well to pirtobrutinib therapy.
Pirtobrutinib is a useful treatment option to temporarily manage Richter’s transformation, but long-term treatments are still needed.
On Dec. 1, 2023, pirtobrutinib received accelerated approval from the FDA for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) patients who had failed two prior lines of therapy, including a BTK inhibitor (BTKi) and a BCL-2 inhibitor.
One click to our most popular content.
